MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Department of Molecular Neuroscience and MRC Centre for Neuromuscular Diseases, Institute of Neurology, Queen Square, London, UK.
Lancet Neurol. 2017 Jan;16(1):88-96. doi: 10.1016/S1474-4422(16)30350-7.
Inherited diseases caused by unstable repeated DNA sequences are rare, but together represent a substantial cause of morbidity. Trinucleotide repeat disorders are severe, usually life-shortening, neurological disorders caused by nucleotide expansions, and most have no disease-modifying treatments. Longer repeat expansions are associated with genetic anticipation (ie, earlier disease onset in successive generations), although the differences in age at onset are not entirely accounted for by repeat length. Such phenotypic variation within disorders implies the existence of additional modifying factors in pathways that can potentially be modulated to treat disease.
A genome-wide association study detected genetic modifiers of age at onset in Huntington's disease. Similar findings were seen in the spinocerebellar ataxias, indicating an association between DNA damage-response and repair pathways and the age at onset of disease. These studies also suggest that a common genetic mechanism modulates age at onset across polyglutamine diseases and could extend to other repeat expansion disorders. Genetic defects in DNA repair underlie other neurodegenerative disorders (eg, ataxia-telangiectasia), and DNA double-strand breaks are crucial to the modulation of early gene expression, which provides a mechanistic link between DNA repair and neurodegeneration. Mismatch and base-excision repair are important in the somatic expansion of repeated sequences in mouse models of trinucleotide repeat disorders, and somatic expansion of the expanded CAG tract in HTT correlates with age at onset of Huntington's disease and other trinucleotide repeat disorders. WHERE NEXT?: To understand the common genetic architecture of trinucleotide repeat disorders and any further genetic susceptibilities in individual disorders, genetic analysis with increased numbers of variants and sample sizes is needed, followed by sequencing approaches to define the phenotype-modifying variants. The findings must then be translated into cell biology analyses to elucidate the mechanisms through which the genetic variants operate. Genes that have roles in the DNA damage response could underpin a common DNA repeat-based mechanism and provide new therapeutic targets (and hence therapeutics) in multiple trinucleotide repeat disorders.
由不稳定重复 DNA 序列引起的遗传疾病很少见,但它们共同构成了发病率的重要原因。三核苷酸重复障碍是由核苷酸扩展引起的严重、通常会缩短寿命的神经退行性疾病,大多数疾病没有可改变疾病进程的治疗方法。较长的重复扩展与遗传预期(即,在连续几代中更早地发病)相关,尽管发病年龄的差异并不能完全由重复长度来解释。这种疾病内的表型变异意味着在可能被调节以治疗疾病的途径中存在其他修饰因子。
全基因组关联研究检测到亨廷顿病发病年龄的遗传修饰因子。在脊髓小脑共济失调中也观察到了类似的发现,这表明 DNA 损伤反应和修复途径与疾病发病年龄之间存在关联。这些研究还表明,一种常见的遗传机制可以调节多聚谷氨酰胺疾病的发病年龄,并可能扩展到其他重复扩展障碍。DNA 修复的遗传缺陷是其他神经退行性疾病(例如,共济失调毛细血管扩张症)的基础,而 DNA 双链断裂对于早期基因表达的调节至关重要,这为 DNA 修复和神经退行性变之间提供了一种机制联系。错配和碱基切除修复在三核苷酸重复障碍的小鼠模型中重复序列的体细胞扩展中很重要,并且 HTT 中扩展的 CAG 片段的体细胞扩展与亨廷顿病和其他三核苷酸重复障碍的发病年龄相关。
下一步是什么?:为了了解三核苷酸重复障碍的常见遗传结构以及个体疾病中的任何其他遗传易感性,需要进行具有更多变体和样本量的遗传分析,然后采用测序方法来定义表型修饰变体。然后必须将这些发现转化为细胞生物学分析,以阐明遗传变体发挥作用的机制。在 DNA 损伤反应中起作用的基因可能是基于共同的 DNA 重复机制的基础,并为多种三核苷酸重复障碍提供新的治疗靶点(因此也提供了治疗方法)。